Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

Stock Information for Spyre Therapeutics Inc Com (New)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Spyre Therapeutics Inc Com (New)

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Aeglea BioTherapeutics Announces Grants of Inducement Awards
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE)
Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Aeglea BioTherapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Aeglea BioTherapeutics Announces Grants of Inducement Awards

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.